On November 9, five leading public offerings, including Huaxia Fund, Huaan Fund, Harvest Fund, Bosera Fund and ICBC Credit Suisse Fund, reported the Shanghai Securities Science and Technology Innovation Board Biomedical Transactional Open-ended Index Fund (hereinafter referred to as "Science and Technology Bio"), and the Science and Technology Innovation Biomedical ETF will be added to the Science and Technology Innovation Board sub-industry thematic ETF.
According to Harvest Fund, Kechuang Biotech selected 50 securities of companies in the fields of biomedicine, biomedical engineering, and other biological industries with large market capitalization as the index sample, with outstanding hard technology attributes, providing the industry with a performance benchmark
for biomedicine on the science and technology innovation board.
Huaan Fund pointed out that the biomedical sector of the Science and Technology Innovation Board focuses on the concept of medical innovative devices + innovative drugs, including the growth and innovation direction of the pharmaceutical industry such as medical consumables, medical equipment, biological products, chemical pharmaceuticals, and medical services; The companies in the sector as a whole are in a period of rapid growth, and the total market value of the constituent stocks is mainly distributed in the range of 10 billion to 30 billion yuan, which reflects the characteristics of small and medium-cap innovative pharmaceutical stocks and has good investment flexibility
.
Wind predicts that in 2022, the predicted net profit of the Science and Technology Innovation Biological Index will reach 97.
41%, which has a large room for growth and is much higher than other indexes
.
As of September 30, 2022, the price-to-earnings ratio of Kechuang Biotech reached 106.
68 times, which is much higher than other biomedical indexes
.
At present, pharmaceutical ETFs are still the thematic ETFs
that the market is paying attention to.
Since the beginning of this year, the share of pharmaceutical ETFs has increased significantly, of which the pharmaceutical ETF and medical ETF have both increased by more than 10 billion shares during the year, increasing by 16.
695 billion and 14.
736 billion respectively
.
Recently, affected by a series of favorable policies and the good performance of the third quarter, the pharmaceutical sector has experienced a round of rebound, Choice data shows that from October 12 to November 8, the pharmaceutical and biological sector as a whole rose by more than 13%.
Among them, 4 stocks rose by more than 100%, and 22 stocks rose by more than 50%.
Among them, Huasen Pharmaceutical rose by 132%, CanSino and Zhongsheng Pharmaceutical rose by 115% and 104%
respectively.
Institutions have also been active recently, researching pharmaceutical companies
.
Choice data shows that since October, listed companies in the pharmaceutical and biological sector have been surveyed by securities firms more than 1,300 times, mainly investigating companies
in medical devices and other segments.
China Galaxy Securities recommends paying attention to the sentiment and strength
of the next pharmaceutical policy.
The next key node to observe the policy will be the national negotiation of innovative drug medical insurance at the end of November, and it is expected that this medical insurance negotiation will serve as a window
to observe whether the drug policy is marginally loose.
Essence Securities believes that the negotiation policy of medical insurance renewal of innovative drugs in this medical insurance negotiation is expected to improve, according to the relevant answers issued by the Medical Insurance Bureau, the new indications of innovative drugs will be included in the scope of simple renewal consideration, and the price reduction rate is expected to narrow when new indications of innovative drugs are included in medical insurance in the future, which is conducive to the long-term volume of
innovative drugs.
In terms of medical devices, policies continue to help the development of medical devices, especially under the wind of medical "new infrastructure", the pace of import substitution of domestic medical devices will accelerate
.
From the perspective of basic factors, under the background of the aging of the Chinese population, the number of patients with tumors and cardiovascular diseases has increased, the ability of Chinese people to pay has improved, the growth demand of the medical device market is large, and there are many unmet clinical needs
in the Chinese market.
Deppon Securities expects that as the people's pursuit of health continues to improve, the domestic demand for medical equipment will accelerate in the next three years, and the market space is expected to continue to expand
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
